Form 990 for tax year 2023
Filed by THE ALBERT B SABIN VACCINE INSTITUTE INC.
Totals
- Total revenue
- $40,137,500
- Total expenses
- $42,166,765
- Contributions and grants received
- $676,914
- Grants paid
- $3,064,520
- Program service revenue
- $39,331,759
- Investment income
- $128,827
- Other revenue
- $0
- Total assets, end of year
- $15,385,516
- Total liabilities, end of year
- $3,076,842
- Net assets or fund balances, end of year
- $12,308,674
- Program services expenses (Part IX)
- $37,285,537
- Management and general expenses
- $4,603,000
- Fundraising expenses
- $278,228
- Program service expenses (Part III)
- $37,285,537
Program services were 88.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1b · Membership dues
$20,355
-
1f · All other contributions, gifts and grants
$656,559
-
2a · Program service revenue: Federal & Other Contracts
total $39,331,759 · related or exempt $39,331,759
-
3 · Investment income
total $98,622 · excluded $98,622
-
7a · Gross sales of assets other than inventory
securities $30,205
-
7b · Less cost or other basis and sales expenses
securities $0
-
7c · Gain or loss
securities $30,205
-
7d · Net gain or loss
total $30,205 · excluded $30,205
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $525,567 · program services $525,567
-
2 · Grants to domestic individuals
total $5,000 · program services $5,000
-
3 · Grants to foreign organizations and individuals
total $2,533,953 · program services $2,533,953
-
5 · Compensation of officers, directors and key employees
total $1,178,448 · program services $866,981 · management and general $280,231 · fundraising $31,236
-
7 · Other salaries and wages
total $6,957,947 · program services $5,270,458 · management and general $1,500,062 · fundraising $187,427
-
8 · Pension plan contributions
total $214,132 · program services $108,757 · management and general $100,666 · fundraising $4,709
-
9 · Other employee benefits
total $718,514 · program services $364,929 · management and general $337,782 · fundraising $15,803
-
10 · Payroll taxes
total $526,269 · program services $268,106 · management and general $241,952 · fundraising $16,211
-
11b · Fees: legal
total $198,387 · program services $120,348 · management and general $78,039
-
11c · Fees: accounting
total $22,340 · management and general $22,340
-
11g · Fees: other
total $24,662,142 · program services $24,436,214 · management and general $221,098 · fundraising $4,830
-
12 · Advertising and promotion
total $45,431 · program services $14,899 · management and general $30,532
-
13 · Office expenses
total $262,141 · program services $159,836 · management and general $100,583 · fundraising $1,722
-
14 · Information technology
total $110,777 · program services $39,597 · management and general $70,272 · fundraising $908
-
16 · Occupancy
total $273,746 · management and general $273,746
-
17 · Travel
total $624,583 · program services $548,030 · management and general $66,375 · fundraising $10,178
-
19 · Conferences, conventions and meetings
total $1,506,570 · program services $1,436,164 · management and general $70,406
-
22 · Depreciation, depletion and amortization
total $429,297 · program services $252,600 · management and general $176,697
-
23 · Insurance
total $147,001 · program services $115,619 · management and general $31,382
-
24a · Other expenses: Loss on lease terminati
total $780,000 · management and general $780,000
-
24b · Other expenses: Recruitment
total $200,191 · program services $170,473 · management and general $29,514 · fundraising $204
-
24c · Other expenses: Dues/subscriptions
total $148,679 · program services $41,486 · management and general $102,193 · fundraising $5,000
-
24d · Other expenses: Miscellaneous
total $95,604 · program services $6,474 · management and general $89,130
-
24e · All other expenses
total $46 · program services $46
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $1,506,086 · end of year $1,511,941
-
2 · Savings and temporary cash investments
beginning of year $7,361,995 · end of year $5,004,912
-
3 · Pledges and grants receivable
beginning of year $9,587,532 · end of year $6,443,274
-
4 · Accounts receivable
beginning of year $89,556 · end of year $11,310
-
9 · Prepaid expenses and deferred charges
beginning of year $506,438 · end of year $306,415
-
10a · Land, buildings and equipment: cost or other basis
$1,721,954
-
10b · Land, buildings and equipment: accumulated depreciation
$1,168,084
-
10c · Land, buildings and equipment, net
beginning of year $730,567 · end of year $553,870
-
11 · Investments: publicly traded securities
beginning of year $444,763 · end of year $523,902
-
14 · Intangible assets
beginning of year $1,201,953 · end of year $949,353
-
15 · Other assets
beginning of year $275,785 · end of year $80,539
-
17 · Accounts payable and accrued expenses
beginning of year $5,814,295 · end of year $1,711,692
-
25 · Other liabilities
beginning of year $1,536,096 · end of year $1,365,150
-
27 · Net assets without donor restrictions
beginning of year $4,311,941 · end of year $5,567,087
-
28 · Net assets with donor restrictions
beginning of year $10,042,343 · end of year $6,741,587
Mission and programs · 2023
Mission
To make vaccines more accessible, enable innovation and expand immunization across the globe.
Activities or mission (Part I)
To make vaccines more accessible, enable innovation and expand immunization.
-
Vaccine Research & DevelopmentThe Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's Research & Development strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public, and private sectors, and promotes open-source research. Ebola has taken the lives of more than 15,000 people in the last many years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is currently developing vaccines for Sudan ebolavirus and Marburg virus diseases based on technology licensed from GSK. The prophylactic vaccine candidates are based on GSK's proprietary ChAd3 platform. In 2019, the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority awarded Sabin a multi-year development contract to advance development of the Marburg and Sudan Ebola vaccines.
Expenses $27,130,238 · Revenue $31,913,858
-
Global ImmunizationDespite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by immunization. Sabin has a vision of a future free from such preventable diseases. Reaching this goal requires efficient vaccine distribution, broad vaccine uptake and equitable access to vaccination services. Through advocacy, capacity development and social, behavioral, and epidemiological research, Sabin advances evidence-based strategies for improved distribution and uptake of vaccines. Sabin's Global Immunization programs focus on turning vaccines into vaccinations by ceding power, resources, and decision-making to community and national stakeholders. They build consensus to mobilize action through stakeholder consortiums and convenings; strengthen the capabilities of local immunization professionals to deliver vaccinations to remote and hard-to-reach settings; co-design implementation research studies with community-based investigators to highlight barriers for vaccine uptake; and apply epidemiology for disease surveillance as well as optimizing vaccine use. Sabin's Boost global community enables immunization professionals to connect with peers and experts, learn skills that build capacity and advance careers, and lead immunization programs in challenging contexts. Sabin's Vaccine Acceptance & Delivery workstream focuses on understanding the social drivers of vaccination decisions to improve uptake and confidence. Sabin's Applied Epidemiology team improves disease outcomes by generating essential epidemiological data for well-designed and efficiently implemented immunization programs and creating cost-effective diagnostics for diseases such as typhoid. Through a variety of mechanisms including the Global HPV Consortium and the Coalition Against Typhoid, Sabin brings together researchers, government officials, immunization specialists, and other stakeholders to support the introduction and expansion of new under-utilized vaccines.
Expenses $10,155,299 · Grants $3,064,520 · Revenue $7,417,901
As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Adegbola Richard
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Baylor Norman
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Djibo Yacine
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Fox Elizabeth
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Hoos Axel
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Libson Jeffrey
Trustee, Secretary
- Total calculated
- $0
- Hours/week
- 2
-
Omer Saad
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Rabinovich Regina
Trustee, Chair
- Total calculated
- $0
- Hours/week
- 2
-
Salisbury David
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Shea Jacqueline
Trustee, Treasurer
- Total calculated
- $0
- Hours/week
- 2
-
Suzich JoAnn
Trustee
- Total calculated
- $0
- Hours/week
- 2
-
Finan Amy
CEO
- Total calculated
- $545,454
- From this org
- $503,726
- From related orgs
- $0
- Other
- $41,728
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $441,106
- Bonus
- $56,000
- Other
- $6,620
- Deferred
- $10,740
- Nontaxable benefits
- $30,988
- Filer's total
- $545,454
-
Gupta Anuradha
President
- Total calculated
- $267,202
- From this org
- $237,447
- From related orgs
- $0
- Other
- $29,755
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $233,131
- Bonus
- $0
- Other
- $4,316
- Deferred
- $2,400
- Nontaxable benefits
- $27,355
- Filer's total
- $267,202
-
DeLeon Kiju
CFO
- Total calculated
- $365,791
- From this org
- $334,456
- From related orgs
- $0
- Other
- $31,335
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $313,638
- Bonus
- $15,000
- Other
- $5,818
- Deferred
- $12,265
- Nontaxable benefits
- $19,070
- Filer's total
- $365,791
-
King Thomas
VP, Nonclinical
- Total calculated
- $370,639
- From this org
- $316,466
- From related orgs
- $0
- Other
- $54,173
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $291,834
- Bonus
- $20,000
- Other
- $4,632
- Deferred
- $12,017
- Nontaxable benefits
- $42,156
- Filer's total
- $370,639
-
Vert-Wong Ekaterina
VP, Portfolio & Alliance M
- Total calculated
- $367,687
- From this org
- $312,948
- From related orgs
- $0
- Other
- $54,739
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $290,376
- Bonus
- $20,000
- Other
- $2,572
- Deferred
- $12,017
- Nontaxable benefits
- $42,722
- Filer's total
- $367,687
-
Garrett Denise
VP, Applied Epidemiology
- Total calculated
- $330,133
- From this org
- $293,579
- From related orgs
- $0
- Other
- $36,554
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $265,528
- Bonus
- $18,000
- Other
- $10,051
- Deferred
- $10,574
- Nontaxable benefits
- $25,980
- Filer's total
- $330,133
-
Williams Michelle
VP, Operations and HR
- Total calculated
- $308,159
- From this org
- $277,693
- From related orgs
- $0
- Other
- $30,466
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $263,974
- Bonus
- $11,000
- Other
- $2,719
- Deferred
- $10,674
- Nontaxable benefits
- $19,792
- Filer's total
- $308,159
-
Lopez Antonio Gonzalez
VP
- Total calculated
- $278,542
- From this org
- $246,356
- From related orgs
- $0
- Other
- $32,186
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $243,484
- Bonus
- $0
- Other
- $2,872
- Deferred
- $5,833
- Nontaxable benefits
- $26,353
- Filer's total
- $278,542
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.
Schedule J
Answered yes
- 3 · Compensation committee
- 3 · Independent compensation consultant
- 3 · Form 990 of other organizations
- 3 · Written employment contract
- 3 · Compensation survey or study
- 3 · Approval by the board or compensation committee
Answered no
- 4a · Severance or change-of-control payment
- 4b · Supplemental nonqualified retirement plan
- 4c · Equity-based compensation arrangement
- 5a · Pay contingent on this organization's revenues
- 5b · Pay contingent on a related organization's revenues
- 6a · Pay contingent on this organization's net earnings
- 6b · Pay contingent on a related organization's net earnings
- 7 · Other non-fixed payments
- 8 · Paid under the initial-contract exception
Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.
Grants on this return
-
$254,867
Outbreak modeling
-
$78,844
Submission and approval of midline reports
-
Vaccine Acceptance journalist mentoring grant
-
Massachusetts General Hospital
$60,000
Epidemiology study site
-
University Of California Davis
$35,000
Epidemiology study site
-
Vaccine Acceptance Small Grants Program awardee
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 12 November 2024
- IRS schema version
- 2023v5.1
- Source object
- 202413179349302236
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.